Biopharmaceutical firm Angion Biomedica has received approval from the US Food and Drug Administration (FDA) to start the Phase II GUard Against Renal Damage (GUARD) trial of investigational drug BB3 in patients with acute kidney injury (AKI).

Discovered by Angion, BB3 is a proprietary small molecule that mimics the activity of hepatocyte growth factor (HGF).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to the firm, the investigational drug showed organ protective and regenerative therapeutic effects in preclinical models of AKI.

Angion Biomedica president and CEO Dr Itzhak Goldberg said: “We are pleased to receive FDA clearance to evaluate BB3 in patients at high risk for acute kidney injury.

“The GUARD study complements our Phase III study on BB3 in renal transplant patients presenting with delayed graft function, another form of AKI.”

The company has designed the trial to assess the potential of BB3 to treat AKI in patients who undergo open heart surgery and require the use of cardiopulmonary bypass.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GUARD is a multicentre, randomised, placebo-controlled and double-blind trial that will enrol around 100 patients in the US.

Angion said that the study will include patients that have risk factors for AKI, including existing kidney disease, previous cardiac surgery, compromised heart function, advanced age, and diabetes.

University of Maryland School of Medicine nephrology division head and medicine professor Dr Matthew Weir said: “The evaluation of BB3 to treat patients at risk for AKI, and Angion’s additional Phase III clinical trial of BB3 to treat delayed graft function in renal transplant patients, are both very exciting.”